From April 9 to 11, 2025, the CPHI Japan Pharmaceutical Ingredients Exhibition was grandly held at the Tokyo International Exhibition Center. As one of the most influential events in the pharmaceutical industry in Asia, this year’s exhibition covered an area of 26,000 square meters and attracted over 650 exhibitors from around the world. The event spanned the entire pharmaceutical industry chain, from active pharmaceutical ingredients (APIs) and biologics to intelligent pharmaceutical equipment, drawing more than 25,000 professional visitors for networking and discussions.

Jiudian Pharmaceutical, led by General Manager Mr. Yang, attended the exhibition with its International Expansion Department team, the Dianyukang Pharmaceutical team, and a selection of its key products. The company showcased a range of advantageous APIs and excipients, including mebeverine maleate, aluminum magnesium carbonate, sodium caprylate, and calcium hydrogen phosphate, as well as a series of finished products such as Jiuxiangyan® Yuling Ointment, Jiuyue® Anti-Inflammatory and Pain Relief Patch, Jiudian® Siwu Ointment, and Dianxiaonuan® Steam Eye Masks.

The Jiudian Pharmaceutical booth attracted a large number of representatives from pharmaceutical companies, distributors, and agents who came to discuss potential collaborations. The International Expansion Department and Dianyukang team worked closely together to introduce the company’s product advantages, R&D innovations, and future development strategies. They actively sought international cooperation opportunities, further advancing the company’s products into global markets. Notably, Jiudian Pharmaceutical made significant progress in its meetings with Japanese clients and agents. Collaboration on projects including rabeprazole sodium, loxoprofen sodium, and sodium caprylate advanced considerably, and discussions on new drug development directions helped the company define its next-phase work plan.

The Japanese market has long been a focal point for global high-end markets, with its strong economic power, mature consumer mindset, and well-established healthcare system making it a key battleground for many pharmaceutical companies. Jiudian Pharmaceutical places great importance on the Japanese market, and General Manager Yang’s presence at the exhibition for in-depth market research demonstrated the company’s commitment to the Japanese market and its focus on new drugs and projects.

Through this research, Jiudian Pharmaceutical plans to leverage its R&D capabilities and align its resources with the specific needs of the Japanese market. The company intends to increase investment in R&D, accelerate the development process, and introduce more innovative drugs that meet the demands of the Japanese market. Furthermore, based on its sharp market insights, Jiudian Pharmaceutical will make more forward-looking and strategic decisions to ensure its new projects have strong market potential and profitability, laying a solid foundation for the company’s continued stable growth in Japan and the global high-end pharmaceutical market.